Tag Archives: biotechnology law

101 Rejections Under the Guidelines: Mayo and Myriad “Go Viral”

Posted on September 4, 2014 by Warren Woessner

This is a guest post from Hans Sauer, Deputy General Counsel, Intellectual Property for BIO. “Recently, I set out to find real-world examples of recent rejections under the USPTO Guidance, to do my own sampling rather than rely on reported … Continue reading →

Posted in Claim Interpretation | Tagged , , , , , , , , , , , , | 1 Comment

BIO IP & Diagnostics Symposium

Posted on September 2, 2014 by Warren Woessner

Warren Woessner will be moderating a panel on university-industry (from start-ups to big pharma) partnering in the area of companion diagnostics and personalized medicine at the BIO IP and Diagnostics Symposium, September 26th at the Alexandria Hilton. Since the first two … Continue reading →

Posted in Conferences and Classes | Tagged , , , , , | Leave a comment

FDA’s New Biosimilars Guidance

Posted on August 11, 2014 by Warren Woessner

The following has been posted with the permission of their authors James E. Valentine and James C. Shehan of Hyman, Phelps & McNamara as part of their FDA Law Blog. *** August 09, 2014 FDA’s New Biosimilars Guidance Has Sponsors … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | Leave a comment

Fed. Cir.: Antitrust Issues Can Arise From Hatch-Waxman Litigation

Posted on August 7, 2014 by Warren Woessner

In Tyco Healthcare Group v. Mutual Pharm. Co., App. no. 13-1386 (Fed. Cir. August 6, 2014), a divided panel of the court reversed a district court’s summary judgment ruling dismissing antitrust charges brought by ANDA filer Mutual against patent-holder Tyco. (A … Continue reading →

Posted in Antitrust Issues | Tagged , , , , , , , , | Leave a comment